Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Alphabets quarterly earnings miss and heavy AI-infrastructure spending have driven a sharp selloff, with traders debating cash-flow pressure and slowing search-ad monetization against strong Cloud growth and Gemini adoption. Some view the reaction as an overreaction and are buying the dip, while others question whether AI investment can generate returns quickly enough.

Iovances announcement of positive Phase 2 lifileucel results in previously treated metastatic non-small cell lung cancer, with detailed data and a precision-medicine update still to come, is driving attention. Traders are broadly bullish on the potential to extend the therapy beyond melanoma, while some caution that the headline lacks detailed results and could lead to a sell the news reaction.

Alphabets earnings miss sparked a sharp selloff, with traders focused on heavy AI infrastructure spending, weaker cash flow, and concerns about search growth and AI monetization. Bulls counter that strong Google Cloud growth shows AI demand is materializing and call the decline an overreaction, while bears question whether the spending will generate adequate returns.

Reported talks to acquire Lumentum are driving discussion, with traders weighing the strategic value of securing scarce optical components for AI data centers against the potential financing, debt, and shareholder-dilution risks. No deal is final, and opinions are split on whether the acquisition would strengthen Marvell or burden shareholders.

ServiceNows mixed quarterly results and softer Q4 contracted-revenue growth outlook triggered a sharp selloff, despite strong revenue growth and a higher AI target. Traders debate whether the reaction is an overdone reset or a warning about slowing growth, rich expectations, and AI disruption risks for software companies.

SELLAS said its Phase 3 REGAL AML trial reached the 80th event, triggering final analysis, with preliminary topline results expected this quarter; the update disclosed no survival benefit. Traders debated the sharp selloff, with bulls treating it as a buying opportunity ahead of the binary readout and bears emphasizing the risk that the trial may fail.

LITE is drawing attention over reports that Marvell is in advanced talks to acquire it, a potential deal tied to demand for scarce optical components used in AI data centers. Traders see strategic value in the combination but debate whether Marvell can finance it without substantial dilution or debt; no agreement has been confirmed, and the rumor has fueled volatile trading.

Fortinets sharp selloff after quarterly results is dominating discussion, despite a revenue and earnings beat and higher full-year guidance. Traders point to slower product and billings growth, weaker margins, and a reduced service outlook as reasons for disappointment, while others call the reaction excessive given the headline results; the decline is also weighing on other cybersecurity stocks.

Intellia shares are drawing attention alongside other gene-editing stocks after the FDA proposed a pathway that could streamline development of personalized gene-editing treatments. Traders are debating how directly the draft guidance benefits NTLA, while also focusing on lonvo-zs regulatory path and the stocks sharp volatility.

A nonbinding take-private proposal from a Trian-led investor group has put Wendys in focus, with an independent board committee evaluating the offer. Traders largely call it too low and debate whether the board will reject or negotiate for more, while some speculate about competing bids and a short squeeze.